Episode one of the Colonoscopy Practice and Quality chapter treats screening colonoscopy as a chain of dependencies where the weakest link governs the outcome. The organizing idea: colorectal cancer has a long precursor and a survivable early stage, so everything from the starting age to the withdrawal time exists to make prevention real rather than nominal. It walks the modality menu with the rule that any positive non-invasive test commits the patient to colonoscopy, then the split-dose preparation physiology that delivers a clean right colon. It closes on the detection metrics, adenoma detection rate as the single most validated quality measure and sessile serrated lesion detection rate as its complement on the serrated pathway. Topics covered Colorectal cancer screening rationale USPSTF age forty-five and the upper bound High-risk starting ages and intervals The screening modality menu Split-dose bowel preparation physiology Boston Bowel Preparation Scale adequacy Cecal intubation rate and withdrawal time Adenoma detection rate Sessile serrated lesion detection and technology Key decisions Average-risk screening starts at age forty-five, runs routinely through seventy-five, is individualized from seventy-six to eighty-five, and is generally not offered after eighty-five because lead time exceeds residual life expectancy. Any positive non-invasive test, whether FIT, multi-target stool DNA, CT colonography, or Shield, is an indication for diagnostic colonoscopy, and repeating or switching the stool test is not a path back to safety. Split-dose preparation with the second dose finished four to eight hours before the procedure is superior to single-dose evening prep, and PEG-electrolyte is the non-fermentable standard when polypectomy is anticipated because fermentable mannitol risks hydrogen-gas explosion under electrocautery. Adequate preparation requires a Boston Bowel Preparation Scale total at or above six with no individual segment below two, and inadequate prep brings the patient back within one year rather than continuing standard surveillance. Cecal intubation rate should be at or above ninety-five percent for screening with photo documentation of the appendiceal orifice and ileocecal valve, and withdrawal time should be at least six minutes diagnostic and eight to nine minutes for a negative screening exam. Adenoma detection rate is benchmarked around thirty to thirty-five percent in mixed screening populations, with each one percent absolute increase associated with roughly a three percent decrease in interval cancer risk. Minimum acceptable sessile serrated lesion detection rate is approximately six to seven percent, and any proximal hyperplastic polyp ten millimeters or larger is treated as a sessile serrated lesion for surveillance. For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com. Questions or feedback: [email protected].

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related